Compare OXM & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | CRMD |
|---|---|---|
| Founded | 1942 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.3M | 695.9M |
| IPO Year | 1994 | 2009 |
| Metric | OXM | CRMD |
|---|---|---|
| Price | $37.22 | $7.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $38.00 | $14.83 |
| AVG Volume (30 Days) | 349.7K | ★ 850.9K |
| Earning Date | 06-10-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | ★ 1.00 | 0.43 |
| Revenue | ★ $1,477,834,000.00 | $311,709,000.00 |
| Revenue This Year | $2.85 | $0.30 |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $37.50 | ★ $17.47 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $30.57 | $6.13 |
| 52 Week High | $51.61 | $14.96 |
| Indicator | OXM | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.